CD44 and prostate carcinoma: Previous reports have indicated that miR-145 transfection inhibits tumoroid formation in prostate cancer cells, alluding to the decrease in self-renewal capacity of cancer stem cells, due to inhibition of the CD133 and CD44 markers, along with the Oct4, c-Myc and Klf4 transcription factors related to cell pluripotentiality [42].